BR112012024785A2 - antagonista do receptor de cgrp - Google Patents
antagonista do receptor de cgrpInfo
- Publication number
- BR112012024785A2 BR112012024785A2 BR112012024785A BR112012024785A BR112012024785A2 BR 112012024785 A2 BR112012024785 A2 BR 112012024785A2 BR 112012024785 A BR112012024785 A BR 112012024785A BR 112012024785 A BR112012024785 A BR 112012024785A BR 112012024785 A2 BR112012024785 A2 BR 112012024785A2
- Authority
- BR
- Brazil
- Prior art keywords
- cgrp receptor
- cgrp
- compound
- receptor antagonist
- antagonist
- Prior art date
Links
- 239000003735 calcitonin gene related peptide receptor antagonist Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- -1 3- (7-methyl-1h-indazol-5-yl) -1- (4- (1-methylpiperidin-4-yl) piperazin -1-yl) -1-oxopropan-2-yl Chemical group 0.000 abstract 1
- 108010078311 Calcitonin Gene-Related Peptide Receptors Proteins 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010060800 Hot flush Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 102000008323 calcitonin gene-related peptide receptor activity proteins Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000005796 circulatory shock Effects 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 230000009245 menopause Effects 0.000 abstract 1
- 230000001272 neurogenic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000024883 vasodilation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
antagonista do receptor de cgrp. a descrição em geral diz respeito ao composto de fórmula i, (r)-n-(3-(7-metil-1h-indazol-5-il)-1-(4-(1-metilpiperidin-4-il)piperazin-1-il)-1-oxopropan-2-il)-4-(2-oxo-1,2-di-hidroquinolin-3-il)piperidino-1-carboxamida, incluindo sais farmaceuticamente aceitáveis, que é um antagonista do receptor de cgrp. a descrição também diz respeito às composições farmacêuticas e métodos para usar o composto no tratamento de distúrbios relacionados a cgrp incluindo enxaquecas, vasodilatação neurogênica, inflamação neuroênica, lesão térmica, choque circulatório, fogacho associado com menopausa, doenças inflamatórias das vias aéreas tais como asma, doença pulmonar obstrutiva crônica (copd), e câncer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31901510P | 2010-03-30 | 2010-03-30 | |
| US61/319,015 | 2010-03-30 | ||
| PCT/US2011/028168 WO2011123232A1 (en) | 2010-03-30 | 2011-03-11 | Cgrp receptor antagonist |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112012024785A2 true BR112012024785A2 (pt) | 2016-06-07 |
| BR112012024785A8 BR112012024785A8 (pt) | 2017-10-17 |
| BR112012024785B1 BR112012024785B1 (pt) | 2020-12-01 |
Family
ID=43896902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012024785-9A BR112012024785B1 (pt) | 2010-03-30 | 2011-03-11 | antagonista do receptor de cgrp, seu uso e composição farmacêutica que o compreende |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US8481546B2 (pt) |
| EP (1) | EP2552906B1 (pt) |
| JP (1) | JP5908455B2 (pt) |
| KR (3) | KR101854249B1 (pt) |
| CN (1) | CN102834388B (pt) |
| AR (1) | AR080746A1 (pt) |
| AU (1) | AU2011233627B2 (pt) |
| BR (1) | BR112012024785B1 (pt) |
| CA (1) | CA2794950C (pt) |
| CL (1) | CL2012002739A1 (pt) |
| CY (1) | CY1117593T1 (pt) |
| DK (1) | DK2552906T3 (pt) |
| EA (1) | EA022815B1 (pt) |
| ES (1) | ES2562610T3 (pt) |
| HK (1) | HK1174914A1 (pt) |
| HR (1) | HRP20160287T1 (pt) |
| HU (1) | HUE028735T2 (pt) |
| IL (1) | IL221665A (pt) |
| MX (1) | MX2012010725A (pt) |
| NZ (1) | NZ603231A (pt) |
| PE (1) | PE20130340A1 (pt) |
| PL (1) | PL2552906T3 (pt) |
| PT (1) | PT2552906E (pt) |
| RS (1) | RS54608B1 (pt) |
| SG (1) | SG183918A1 (pt) |
| SI (1) | SI2552906T1 (pt) |
| SM (1) | SMT201600078B (pt) |
| TW (1) | TWI483937B (pt) |
| WO (1) | WO2011123232A1 (pt) |
| ZA (1) | ZA201207292B (pt) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201519196D0 (en) * | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
| GB201519194D0 (en) * | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP receptor antagonists |
| GB201519195D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
| GB201707938D0 (en) | 2017-05-17 | 2017-06-28 | Univ Sheffield | Compounds |
| US12030868B2 (en) * | 2018-10-13 | 2024-07-09 | Pfizer Ireland Pharmaceuticals | Prodrugs of CGRP antagonists |
| EP3911409A4 (en) * | 2019-01-20 | 2022-10-19 | Biohaven Pharmaceutical Holding Company Ltd. | CGRP ANTAGONISTS FOR TREATMENT OF BREAKTHROUGHT MIGRAINE |
| EP3952899A1 (en) | 2019-04-11 | 2022-02-16 | R.P. Scherer Technologies, LLC | Formulation for oral delivery of proteins, peptides and small molecules with poor permeability |
| JP2023507094A (ja) * | 2019-12-17 | 2023-02-21 | バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッド | Ｃｇｒｐ阻害剤の鼻腔内医薬組成物 |
| KR20230088442A (ko) * | 2020-11-19 | 2023-06-19 | 화이자 아일랜드 파마슈티컬즈 | Cgrp 억제제의 개선된 전달을 위한 조성물 |
| KR20230157986A (ko) | 2021-03-02 | 2023-11-17 | 체게에르페 다이어그노스틱스 게엠베하 | 편투통 발생의 치료 및/또는 저감 |
| WO2022217008A1 (en) | 2021-04-09 | 2022-10-13 | Teva Czech Industries S.R.O | Solid state forms of zavegepant and process for preparation thereof |
| WO2023026205A1 (en) | 2021-08-24 | 2023-03-02 | Cgrp Diagnostics Gmbh | Preventative treatment of migraine |
| WO2024046223A1 (zh) * | 2022-08-30 | 2024-03-07 | 熙源安健医药（上海）有限公司 | 吲唑甲酰胺类衍生物及其制备方法和用途 |
| WO2024100599A1 (en) | 2022-11-09 | 2024-05-16 | Teva Czech Industries S.R.O. | Solid state forms of zavegepant hydrochloride and process for preparation thereof |
| CN116003387B (zh) * | 2022-11-20 | 2024-03-26 | 药康众拓(北京)医药科技有限公司 | 一种氘代吲唑丙酰胺类化合物、药物组合物和用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2487976C (en) * | 2002-06-05 | 2011-07-26 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
| US7220862B2 (en) | 2002-06-05 | 2007-05-22 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
| EP1722792A1 (de) | 2004-03-03 | 2006-11-22 | Boehringer Ingelheim International GmbH | Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel |
| US7834007B2 (en) | 2005-08-25 | 2010-11-16 | Bristol-Myers Squibb Company | CGRP antagonists |
| CN101495480B (zh) * | 2006-05-03 | 2013-07-10 | 百时美施贵宝公司 | 作为降钙素基因相关肽受体拮抗剂的受限化合物 |
| WO2010006168A2 (en) | 2008-07-09 | 2010-01-14 | University Of Rochester | Methods of treating cancer using and agent that modulates activity of the calcitonin-gene related peptide ("cgrp") receptor |
-
2011
- 2011-03-02 US US13/038,550 patent/US8481546B2/en active Active
- 2011-03-11 ES ES11710087.5T patent/ES2562610T3/es active Active
- 2011-03-11 NZ NZ603231A patent/NZ603231A/en unknown
- 2011-03-11 PL PL11710087T patent/PL2552906T3/pl unknown
- 2011-03-11 SI SI201130765A patent/SI2552906T1/sl unknown
- 2011-03-11 MX MX2012010725A patent/MX2012010725A/es active IP Right Grant
- 2011-03-11 KR KR1020177015456A patent/KR101854249B1/ko active IP Right Grant
- 2011-03-11 EA EA201270751A patent/EA022815B1/ru not_active IP Right Cessation
- 2011-03-11 SG SG2012065744A patent/SG183918A1/en unknown
- 2011-03-11 KR KR1020187011875A patent/KR20180049168A/ko not_active Application Discontinuation
- 2011-03-11 CN CN201180016888.2A patent/CN102834388B/zh active Active
- 2011-03-11 JP JP2013502610A patent/JP5908455B2/ja active Active
- 2011-03-11 PT PT117100875T patent/PT2552906E/pt unknown
- 2011-03-11 EP EP11710087.5A patent/EP2552906B1/en active Active
- 2011-03-11 AU AU2011233627A patent/AU2011233627B2/en active Active
- 2011-03-11 HU HUE11710087A patent/HUE028735T2/en unknown
- 2011-03-11 WO PCT/US2011/028168 patent/WO2011123232A1/en active Application Filing
- 2011-03-11 PE PE2012001746A patent/PE20130340A1/es active IP Right Grant
- 2011-03-11 BR BR112012024785-9A patent/BR112012024785B1/pt active IP Right Grant
- 2011-03-11 KR KR1020127028213A patent/KR101747477B1/ko active IP Right Grant
- 2011-03-11 CA CA2794950A patent/CA2794950C/en active Active
- 2011-03-11 DK DK11710087.5T patent/DK2552906T3/en active
- 2011-03-11 RS RS20160164A patent/RS54608B1/en unknown
- 2011-03-30 TW TW100111106A patent/TWI483937B/zh active
- 2011-03-30 AR ARP110101057A patent/AR080746A1/es not_active Application Discontinuation
-
2012
- 2012-08-27 IL IL221665A patent/IL221665A/en active IP Right Grant
- 2012-09-28 ZA ZA2012/07292A patent/ZA201207292B/en unknown
- 2012-09-28 CL CL2012002739A patent/CL2012002739A1/es unknown
-
2013
- 2013-02-19 HK HK13102079.5A patent/HK1174914A1/zh unknown
-
2016
- 2016-03-21 HR HRP20160287TT patent/HRP20160287T1/hr unknown
- 2016-03-21 SM SM201600078T patent/SMT201600078B/xx unknown
- 2016-03-24 CY CY20161100254T patent/CY1117593T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012024785A2 (pt) | antagonista do receptor de cgrp | |
| TN2012000139A1 (en) | Cgrp receptor antagonists | |
| WO2009126530A3 (en) | Piperidine derivatives as cgrp receptor antagonists | |
| CY1122121T1 (el) | N-(5s,6s,9r)-5-amino-6-(2,3-διφθοpoφainyλ)-6,7,8,9-tetpaϋδpo-5h-κυκλοεπτα[β]πυριδιν-9-υλ-4-(2-οξο-2, 3-διϋδρο-1η-ιμιδαζο[4,5-β]πυριδιν-1-υλ)πιπεριδινο-1-καρβοξυλικο αλας | |
| BR112012033715A2 (pt) | inibidores de quinase de regulação de sinal de apoptose. | |
| BRPI0509341A (pt) | anatagonistas de cgrp hetorocìclicos para o tratamento de enxaqueca | |
| BR122019017036B8 (pt) | compostos de arilamidas substituídas por tetrazol, usos dos referidos compostos e composição farmacêutica | |
| BR112015017008A2 (pt) | ftalazinonas e isoquinolinonas como inibidores de rock | |
| MA29432B1 (fr) | Antagonistes du recepteur du glucagon, leur preparation et leurs utilisations therapeutiques | |
| ECSP077398A (es) | Pirimidinas como antagonistas del receptor de prostaglandina d2 | |
| MX2014000341A (es) | Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades. | |
| EA201200876A1 (ru) | Новые антагонисты рецептора ccr2 и их применение | |
| BR112015007182A2 (pt) | inibidores de gdf-8 | |
| TN2014000033A1 (fr) | Indazoles | |
| CL2008001898A1 (es) | Compuestos derivados de pirazinona, inhibidores de p38; proceso de preparacion de estos; composicion farmaceutica que los comprende; combinacion farmaceutica que los comprende; uso para tratar enferemedades pulmonares obstructivas cronicas y asma. | |
| NO20062489L (no) | Heterocykliske anti-migrenemidler | |
| NZ605690A (en) | Oxadiazole inhibitors of leukotriene production | |
| EA201390457A1 (ru) | Полиморфы и соли 6-(1h-индол-4-ил)-4-(5-{[4-(1-метилэтил)-1-пиперазинил]метил}-1,3-оксазол-2-ил)-1h-индазола в качестве ингибиторов pi3k для применения в лечении, например, респираторных расстройств | |
| CL2013000870A1 (es) | Solvato de isopropanol e hidrato de la sal oxalato cristalina del 1-(2-([4-(4-([(r)-2-hidroxi-2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etilamino]metil)fenilcarbamoil)butil]metilcarbamoil)etilpiperidin-4-il ester del acido bifenil-2-ilcarbamico; composicion farmaceutica; y uso para tratar una enfermedad pulmonar, epoc y asma. | |
| EA201001645A1 (ru) | Хинуклидиновые производные в качестве антагонистов мускаринового м3 рецептора | |
| BR112015007641A8 (pt) | Tratamento da doença de alzheimer branda e moderada | |
| WO2007130927A3 (en) | Condensed tricyclic compounds as cgrp-receptor antagonists | |
| NO20084564L (no) | Stramme "Constrained" forbindelser som CGRP-reseptor antagonister | |
| RU2013147196A (ru) | Агонист рецептора 5-нт4 в качестве прокинетического агента | |
| EA201070927A1 (ru) | Двойные фармакофоры-pde4-мускариновые антагонисты |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/03/2011, OBSERVADAS AS CONDICOES LEGAIS. |